Literature DB >> 26166836

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).

M Untch1, N Harbeck2, J Huober3, G von Minckwitz4, B Gerber5, H-H Kreipe6, C Liedtke7, N Marschner8, V Möbus9, H Scheithauer10, A Schneeweiss11, C Thomssen12, C Jackisch13, M W Beckmann14, J-U Blohmer15, S-D Costa16, T Decker17, I Diel18, P A Fasching19, T Fehm20, W Janni21, H-J Lück22, N Maass23, A Scharl24, S Loibl25.   

Abstract

For the first time, this year's St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer, which takes place every two years, was held not in St. Gallen (Switzerland) but - for logistical reasons - in Vienna (Austria) under its usual name. The 2015 St. Gallen International Consensus Conference was the 14th of its kind. As the international panel of the St. Gallen conference consists of experts from different countries, the consensus mirrors an international cross-section of opinions. From a German perspective, it was considered useful to translate the results of the votes of the St. Gallen conference into practical suggestions, particularly in light of the recently updated treatment guideline of the Gynecologic Oncology Group (AGO-Mamma 2015) in Germany. A German group consisting of 14 breast cancer experts, three of whom are members of the international St. Gallen panel, has therefore provided comments on the results of this year's votes at the 2015 St. Gallen Consensus Conference and their impact on clinical care in Germany. The 14th St. Gallen conference once again focused on surgery of the breast and the axilla, radio-oncologic and systemic treatment options for primary breast cancer depending on tumor biology, and the clinical use of multigene assays. The conference also considered targeted therapies for older and for younger patients, including the diagnosis/treatment of breast cancer during and after pregnancy and the preservation of fertility.

Entities:  

Keywords:  St. Gallen consensus; adjuvant therapy; breast cancer; multigene signatures; neoadjuvant therapy

Year:  2015        PMID: 26166836      PMCID: PMC4490924          DOI: 10.1055/s-0035-1546120

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  17 in total

1.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

2.  Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Authors:  Meredith M Regan; Patrick Neven; Anita Giobbie-Hurder; Aron Goldhirsch; Bent Ejlertsen; Louis Mauriac; John F Forbes; Ian Smith; István Láng; Andrew Wardley; Manuela Rabaglio; Karen N Price; Richard D Gelber; Alan S Coates; Beat Thürlimann
Journal:  Lancet Oncol       Date:  2011-10-20       Impact factor: 41.316

3.  Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009).

Authors:  Csaba Polgár; Erik Van Limbergen; Richard Pötter; György Kovács; Alfredo Polo; Jaroslaw Lyczek; Guido Hildebrandt; Peter Niehoff; Jose Luis Guinot; Ferran Guedea; Bengt Johansson; Oliver J Ott; Tibor Major; Vratislav Strnad
Journal:  Radiother Oncol       Date:  2010-02-22       Impact factor: 6.280

4.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

5.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

6.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

7.  Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

Authors:  Masashi Ando; Hideko Yamauchi; Kenjiro Aogi; Satoru Shimizu; Hiroji Iwata; Norikazu Masuda; Naohito Yamamoto; Kenichi Inoue; Shinji Ohono; Katsumasa Kuroi; Tetsutaro Hamano; Tamie Sukigara; Yasuhiro Fujiwara
Journal:  Breast Cancer Res Treat       Date:  2014-04-12       Impact factor: 4.872

8.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

9.  Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).

Authors:  Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-15       Impact factor: 7.038

10.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

View more
  8 in total

1.  First Reported Use of Radiofrequency Identification (RFID) Technique for Targeted Excision of Suspicious Axillary Lymph Nodes in Early Stage Breast Cancer - Evaluation of Feasibility and Review of Current Recommendations.

Authors:  Wolfram Malter; Christian Eichler; Bettina Hanstein; Peter Mallmann; Johannes Holtschmidt
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.

Authors:  Peter Dall; Thorsten Koch; Thomas Göhler; Johannes Selbach; Andreas Ammon; Jochen Eggert; Nidal Gazawi; Daniela Rezek; Arthur Wischnik; Carsten Hielscher; Stella Keitel; Ursula Cirrincione; Axel Hinke; Gabriele Feisel-Schwickardi
Journal:  Oncologist       Date:  2017-02-07

3.  TIPE3 protein promotes breast cancer metastasis through activating AKT and NF-κB signaling pathways.

Authors:  Kaili Lian; Chao Ma; Chunyan Hao; Yan Li; Na Zhang; Youhai H Chen; Suxia Liu
Journal:  Oncotarget       Date:  2017-07-25

4.  Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.

Authors:  E C Inwald; O Ortmann; M Koller; F Zeman; F Hofstädter; M Evert; G Brockhoff; M Klinkhammer-Schalke
Journal:  Breast Cancer Res Treat       Date:  2017-02-15       Impact factor: 4.872

5.  4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.

Authors:  Elisabeth Christine Inwald; M Koller; M Klinkhammer-Schalke; F Zeman; F Hofstädter; M Gerstenhauer; G Brockhoff; O Ortmann
Journal:  Breast Cancer Res Treat       Date:  2015-09-14       Impact factor: 4.872

6.  Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.

Authors:  Justinas Besusparis; Benoit Plancoulaine; Allan Rasmusson; Renaldas Augulis; Andrew R Green; Ian O Ellis; Aida Laurinaviciene; Paulette Herlin; Arvydas Laurinavicius
Journal:  Diagn Pathol       Date:  2016-08-30       Impact factor: 2.644

7.  Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images.

Authors:  Jesuchristopher Joseph; Martine P Roudier; Priya Lakshmi Narayanan; Renaldas Augulis; Vidalba Rocher Ros; Alison Pritchard; Joe Gerrard; Arvydas Laurinavicius; Elizabeth A Harrington; J Carl Barrett; William J Howat
Journal:  Sci Rep       Date:  2019-09-06       Impact factor: 4.379

8.  Multi-Omics Analysis Detects Novel Prognostic Subgroups of Breast Cancer.

Authors:  Quang-Huy Nguyen; Hung Nguyen; Tin Nguyen; Duc-Hau Le
Journal:  Front Genet       Date:  2020-10-15       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.